Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Georgia
Xencor Investigative Site, Tbilisi Moldova
Xencor Investigative Site, Chisinau New Zealand
Xencor Investigative Site, Auckland